SG3199

Cat. No.: CAS No.: Molecular Formula: Molecular Weight: Target: Pathway: Storage:	HY-101161 1595275-71-0 C ₃₃ H ₃₆ N ₄ O ₆ 584.66 DNA Alkylator/Crosslinker; ADC Cytotoxin Cell Cycle/DNA Damage; Antibody-drug Conjugate/ADC Related -20°C, protect from light, stored under nitrogen * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)	$H_{n} = \begin{pmatrix} 0 & - & - & 0 \\ 0 & - & - & 0 \\ - & 0 & - & 0 \\ 0 & - & 0 & - & 0 \\ - & 0 & - & 0 \\ 0 & - & 0 $
---	---	--

SOLVENT & SOLUBILITY

		Solvent Mass Concentration	1 mg	5 mg	10 mg	
	Preparing Stock Solutions	1 mM	1.7104 mL	8.5520 mL	17.1040 mL	
		5 mM	0.3421 mL	1.7104 mL	3.4208 mL	
		10 mM	0.1710 mL	0.8552 mL	1.7104 mL	
	Please refer to the so	lubility information to select the app	propriate solvent.			
In Vivo		1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 3.25 mg/mL (5.56 mM); Clear solution				
		2. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 3.25 mg/mL (5.56 mM); Clear solution				

BIOLOGICAL ACTIVITY		
Description	SG3199 is a cytotoxic DNA minor groove interstrand crosslinking pyrrolobenzodiazepine (PBD) dimer. SG3199 is the released warhead component of the ADC payload Tesirine (SG3249) ^{[1][2]} .	
IC ₅₀ & Target	Pyrrolobenzodiazepines	
In Vitro	SG3199 is potently cytotoxic against a panel of human solid tumour and haematological cancer cell lines with a mean Gl ₅₀ of 151.5 pM. Cells defective in DNA repair protein ERCC1 or homologous recombination repair show increased sensitivity to SG3199 and the drug is only moderately susceptible to multidrug resistance mechanisms ^[1] . SG3199 is highly efficient at producing DNA interstrand cross-links in naked linear plasmid DNA and dose-dependent cross- linking is observed in cells ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	



In Vivo	The in vitro binding of [³ H]-SG3199 to the plasma proteins of rat (Sprague Dawley), cynomolgus monkey and human at concentrations of 0.8, 5 and 50 ng/mL is determined. Plasma protein binding is high in all species; rat ⊠97%, cynomolgus monkey ⊠90% and human ⊠95% ^[1] . Following i.v. administration at 0.1 µg/kg, 0.5 µg/kg and 1 µg/kg, SG3199 shows a very rapid clearance in rats. In the 0.5 µg/kg and 1 µg/kg dose groups, the rapid clearance was between 1000 and 1500 mL/h/kg, with a T _{1/2} between 8 and 42
	minutes ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

• Mol Pharm. 2022 Dec 2.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. John A Hartley, et al. Pre-clinical pharmacology and mechanism of action of SG3199, the pyrrolobenzodiazepine (PBD) dimer warhead component of antibody-drug conjugate (ADC) payload tesirine. Sci Rep. 2018 Jul 11;8(1):10479.

[2]. Francesca Zammarchi, et al. ADCT-402, a PBD dimer-containing antibody drug conjugate targeting CD19-expressing malignancies. Blood. 2018 Mar 8;131(10):1094-1105.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA